New drug combo trial aims to outperform standard chemo for blood cancer

NCT ID NCT01650701

Completed Disease control Sponsor: The Lymphoma Academic Research Organisation Source: ClinicalTrials.gov ↗

Summary

This large, completed Phase 3 trial tested if a combination of the drugs lenalidomide and rituximab could better control follicular lymphoma—a slow-growing but hard-to-cure blood cancer—compared to the standard treatment of rituximab plus chemotherapy. It involved over 1,000 adults with previously untreated disease who needed therapy. The main goals were to see which treatment led to more complete remissions and longer periods without the cancer getting worse.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Atlantic Health Sciences Corp - Saint John Regional Hospital

Halifax, Nova Scotia, Canada
BCCA - Vancouver Cancer Centre

Vancouver, British Columbia, Canada
CHU Claude Huriez

Lille, France
CHU Mont-Godinne

Yvoir, Belgium
CHUM Hopital Notre-Dame

Montreal, Quebec, Canada
Concord Repatriation General Hospital

Concord, New South Wales, Australia
Cross Cancer Institute

Edmonton, Alberta, Canada
Fraser Valley Cancer Centre

Surrey, British Columbia, Canada
Hospital Clínico Universitario de Valencia

Valencia, Spain
Hospital Clínico de Barcelona

Barcelona, Spain
Hospital Costa del Sol

Marbella, Spain
Hospital Ramon y Cajal

Madrid, Spain
Hospital Son Llatzer

Palma, Mallorca, Spain
Hospital Universitario Mutua de Terrassa

Terrassa, Barcelona, Spain
Hospital Universitario Salamanca

Salamanca, Spain
Hospital Universitario Vall d´Hebron

Barcelona, Spain
Hospital Universitario de Canarias

Santa Cruz de Tenerife, Canary Islands, Spain
Hospital Virgen del Rocio

Seville, Andaloucia, Spain
Hospital de la Santa Creu i Sant Pau

Barcelona, Spain
Hôpital de l'Enfant-Jesus, CHU de Quebec

Québec, Quebec, Canada
Institut Català d'Oncologia de Girona (ICO Girona)

Girona, Spain
Instituto Português Oncologia

Lisbon, Portugal
LMU Munchën - Klinikum Grosshadern

München, Germany
McGill University Department of Oncology

Montreal, Quebec, Canada
Medizinische Klinik der Universität Tübingen

Tübingen, Baden-Wurttemberg, Germany
Moncton Hospital

Moncton, New Brunswick, Canada
Nepean Hospital

Penrith, New South Wales, Australia
Policlinico Sant'Orsola-Malpighi

Bologna, Italy
Sant'Andrea Hospital

Rome, Lazio, Italy
Saskatoon Cancer Centre

Saskatoon, Saskatchewan, Canada
Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada
Tom Baker Cancer Centre

Calgary, Alberta, Canada
UHN-Princess Margaret Hospital

Toronto, Ontario, Canada
Uniklinik Köln

Cologne, Nordrhein, Germany
Wollongong Hospital

Wollongong, New South Wales, Australia

Conditions

Explore the condition pages connected to this study.

FOLLICULAR LYMPHOMA